Request Demo
Last update 25 Oct 2025
Octreotide pamoate
Last update 25 Oct 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms Octreotide pamoate (USAN), OP-LAR, SMS 201-995 pa + [3] |
Target |
Action agonists |
Mechanism SSTR agonists(Somatostatin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC49H66N10O10S2.C23H16O6 |
InChIKeyKFWJVABDRRDUHY-XJQYZYIXSA-N |
CAS Registry135467-16-2 |
Sequence Code 19721
Related
5
Clinical Trials associated with Octreotide pamoateNCT01469338
A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
EUCTR2007-004994-25-GB
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotide
NCT00432068
A Phase I , Open Label, Single Center, Dose Escalation Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of a New Extended Long-acting Formulation of Octreotide Pamoate Administered i.m. in Healthy Cholecystectomized Volunteers
100 Clinical Results associated with Octreotide pamoate
Login to view more data
100 Translational Medicine associated with Octreotide pamoate
Login to view more data
100 Patents (Medical) associated with Octreotide pamoate
Login to view more data
2,647
Literatures (Medical) associated with Octreotide pamoate01 Jul 2024European Journal of Nuclear Medicine and Molecular Imaging
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
Article
Author: McDougall, Lisa ; van der Meulen, Nicholas P ; Müller, Cristina ; Fani, Melpomeni ; Westerbergh, Frida ; Geistlich, Susanne ; Christ, Emanuel ; Fricke, Julia ; Bernhardt, Peter ; Schibli, Roger ; Wild, Damian ; Nicolas, Guillaume P ; Borgna, Francesca ; Favaretto, Chiara
Here, we report on the first patient (78-yr-old man) with a metastatic, hormone-active (carcinoid syndrome) ileal neuroendocrine tumor (G1, Ki-67, < 3%), who received a test infusion of 1 GBq [161Tb]Tb-DOTA-LM3 in an ongoing prospective Phase 0 study.So far, the patient received long-acting octreotide, which was stopped 2 mo before [161Tb]Tb-DOTA-LM3 infusion.The 161Tb emits conversion electrons and high quantities of Auger electrons (1213%) with a high linear energy transfer over a short distance (< 40 keV/μm), while Somatostatin receptor subtype 2 antagonists such as DOTA-LM3 bind to many more binding sites, which leads to a much higher tumor accumulation compared to somatostatin receptor subtype 2 agonists.The case presented shows the potential of [161Tb] Tb-DOTA-LM3 as a promising alternative to the current standard peptide receptor radionuclide therapy with [177Lu]Lu-DOTATOC/[ 177Lu]Lu-DOTATATE (Lutathera) for patients with metastatic gastroenteropancreatic neuroendocrine tumors.
01 May 2024Journal of neuro-oncology
Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis
Article
Author: Salgues, Betty ; Guedj, Eric ; Appay, Romain ; Tabouret, Emeline ; Chinot, Olivier ; Horowitz, Tatiana ; Padovani, Laetitia ; Graillon, Thomas
PURPOSE:
Several retrospective studies and meta-analyses of Peptide Radionuclide Radiation Therapy in meningiomas suggest six-month progression-free survival improvement for WHO grade 1 and 2 meningiomas. In the present study, we aimed to evaluate the impact of such treatment on three-dimensional volume growth rate (3DVGR) in nonanaplastic meningiomas.
METHODS:
The authors performed a retrospective study including eight patients treated with Lutathera®. Millimetric 3D T1-weighted with gadolinium enhancement magnetic resonance imaging sequences were requested for volume measurement. Then, tumor growth rate was classified following a previously described 3DVGR classification (Graillon et al.).
RESULTS:
Patients harbored seven WHO grade 2 meningiomas and one aggressive WHO grade 1. All patients, except one, underwent four treatment cycles. 3DVGR significantly decreased at 3, 6, and 12 months after treatment initiation analyzing each lesion separately. Mean and median 3DVGR from all patients were respectively at 29.5% and 44.5%/6 months before treatment initiation, then at 16.5% and 25%/6 months at three months post-treatment initiation, 9.5% and 4.5%/6 months after 6 months, as well as 9.5% and 10.5%/6 months after 12 months. At 3, 6, and 12 months after treatment initiation, 4/8, 6/7, and 5/6 patients were class 2 (stabilization or severe 3DVGR slowdown), respectively. No patient was class 1 at 6 and 12 months, suggesting a lack of drug response.
CONCLUSION:
In nonanaplastic meningiomas, Lutathera®'s antitumoral activity appeared delayed and more likely observed at six months, while no major response was observed under treatment. Moreover, its antitumoral activity persisted for 12-18 months following treatment initiation.
01 May 2024Journal of surgical oncology
Neuroendocrine neoplasms of the gallbladder: A single institute analysis of outcomes and prognostic factors
Article
Author: Ostwal, Vikas ; Bhargav, Prabhat ; Goel, Mahesh ; Nandy, Kunal ; Patkar, Shraddha ; Yadav, Subhash ; Ramaswamy, Anant
Abstract:
Introduction:
Neuroendocrine neoplasms (NENs) are classified as neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed neuroendocrine and nonneuroendocrine neoplasms (MiNENs) according to World Health Organization classification. We present our experience of NENs of the gallbladder (GB) from a high‐volume cancer hospital.
Materials and Methods:
The present study is a retrospective analysis of all patients with GB NENs who presented between January 2015 and June 2023. The patient details and treatment received with follow‐up were noted. The primary endpoint was overall survival (OS).
Results:
A total of 147 patients were included in the study. The median age was 52 (27–81) years. There was a female predominance (70.7%). NEC was the most common subtype (84.4%) followed by MiNEN (12.9%) and NET (2.7%). The most common stage at presentation was metastatic (70.7%) followed by locally advanced (21.8%), and early disease (7.5%). The median follow‐up was 9.92 (1.77–76.06) months. Median OS was 6.14 (3.93–8.35) months. Median OS in patients who received multimodality treatment was 20.20 (17.99–22.41) months versus 4.00 (2.91–5.10) months in those who did not receive it.
Conclusion:
GB NENs are rare, but aggressive tumors with NEC being the most common type. Multimodality treatment yields favorable outcomes. However, the development of better systemic therapy is needed to help improve survival further.
1
News (Medical) associated with Octreotide pamoate25 Sep 2023
Clinical ResultPhase 3Oligonucleotide
100 Deals associated with Octreotide pamoate
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05230 | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Phase 3 | United States | 01 May 1997 | |
| Breast Cancer | Phase 3 | Canada | 01 May 1997 | |
| Gallbladder Diseases | Phase 1 | Belgium | 01 Jan 2007 | |
| Gallbladder Diseases | Phase 1 | France | 01 Jan 2007 | |
| Gallbladder Diseases | Phase 1 | Italy | 01 Jan 2007 | |
| Osteosarcoma | Phase 1 | - | - | |
| Osteosarcoma | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | zfcxppmmiy(zpjpugwsug) = iulfzcubcg qseoausypo (trbuaqvxpd ) View more | Positive | 29 Jan 2019 | |||
zfcxppmmiy(zpjpugwsug) = onsnajsofe qseoausypo (trbuaqvxpd ) View more | |||||||
Phase 3 | 272 | kevjouedxk(upzetbemtt) = Symptomatic hypoglycaemia was the only adverse event observed in treated patients (0.7%) rurgrllrnb (cbfbgugioy ) | - | 01 Jun 2005 | |||
placebo |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free